Calixar raises €1 Million

February 23, 2015

This new round will enable the French biotech company to license-out its isolation technologies for complex therapeutic targets and viral antigens.

Share this post

Secure and boost
your discovery programs

Starting from native material or recombinant systems, we succeed with all types of proteins: Kinases, Phosphatases, Ubiquitins, Epigenetic Proteins, GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins.